A new analysis says the cell and gene therapy (CGT) industry still relies primarily on robust raw-material testing and screening because current viral inactivation methods can be too harsh for sensitive cell therapies and viral vectors. The report points to biopharmaceutical raw materials and ancillary human or animal-origin components as major sources of contamination risk. It also highlights the regulatory and practical tension: downstream virus removal and inactivation processes—developed for protein biologics—may reduce product integrity or vector potency in CGT settings. As a result, the sector leans on comprehensive viral testing programs throughout manufacturing. The piece notes that next-generation technologies such as NGS could expand detection capabilities for adventitious viruses, but quality systems and process controls will remain central until validated methods can support broader inactivation strategies without compromising clinical performance.